Psychopharmacology bulletin · 2020
Demographic Variation in the Use of Prazosin for Treatment of Sleep Disturbance in Combat Veterans with PTSD.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Rubin Miriam L, Copeland Laurel A, Kroll-Desrosiers Aimee R, Knittel Alice G
Аннотация
OBJECTIVES: Off-label use of prazosin for posttraumatic stress disorder-related sleep disturbances (PTSD-SD) is widespread in Veterans Health Administration (VA) settings, but clinical trials have had mixed results. Trial criteria may exclude significant sub-groups, and therefore a 2018 study may not provide the final evidence of prazosin efficacy for PTSD-SD. This study analyzed correlates of prazosin use in Vietnam era (VNE) and Operations Enduring Freedom/Iraqi Freedom (OEF/OIF) cohorts to illustrate patterns of usage in this heterogeneous population.
METHOD: Data extracted on patients with PTSD-SD prescribed prazosin in 2015 described the proportion of days covered (PDC) ≥ 80% and daily dose ≥ 6 mg (therapeutic target dose) over the next 12 months.
RESULTS: Both VNE (n = 41,365) and OEF/OIF (n = 62,984) cohorts had high rates of comorbidity (N = 104,349; 46% hypertension, 22% alcohol use disorder, 14% drug use disorder). Adherence and dosing were low: 19% of veterans achieved PDC ≥ 80%; 7% achieved ≥ 6mg/day (average 2.6 mg/day). In covariate-adjusted models, VNE veterans had better adherence, VNE women had lower rates of therapeutic dosing, and minority race/ethnicity was a strong risk factor for non-adherence. PDC correlated inversely with alcohol/drug disorders.
CONCLUSION: Prazosin is prescribed for PTSD-SD to a diverse clinical population with multiple comorbidities and concurrent medications and is characterized by poor adherence and sub-optimal dosing. Future work should clarify the efficacy of prazosin for subgroups of veterans with PTSD-SD, notably women and racial/ethnic minorities.
METHOD: Data extracted on patients with PTSD-SD prescribed prazosin in 2015 described the proportion of days covered (PDC) ≥ 80% and daily dose ≥ 6 mg (therapeutic target dose) over the next 12 months.
RESULTS: Both VNE (n = 41,365) and OEF/OIF (n = 62,984) cohorts had high rates of comorbidity (N = 104,349; 46% hypertension, 22% alcohol use disorder, 14% drug use disorder). Adherence and dosing were low: 19% of veterans achieved PDC ≥ 80%; 7% achieved ≥ 6mg/day (average 2.6 mg/day). In covariate-adjusted models, VNE veterans had better adherence, VNE women had lower rates of therapeutic dosing, and minority race/ethnicity was a strong risk factor for non-adherence. PDC correlated inversely with alcohol/drug disorders.
CONCLUSION: Prazosin is prescribed for PTSD-SD to a diverse clinical population with multiple comorbidities and concurrent medications and is characterized by poor adherence and sub-optimal dosing. Future work should clarify the efficacy of prazosin for subgroups of veterans with PTSD-SD, notably women and racial/ethnic minorities.